vimarsana.com

Latest Breaking News On - Karolinska development ab nasdaq stockholm - Page 7 : vimarsana.com

Karolinska Development s portfolio company Umecrine Cognition includes first patient in Phase 2 study of golexanolon in primary biliary cholangitis

STOCKHOLM, SWEDEN – April 17, 2023. Karolinska Development AB today announces that its portfolio company Umecrine Cognition has included the first patient in a Phase 2 clinical trial of the. | April 17, 2023

Karolinska institutetViktor drvotaJohan dighedKarolinska development ab nasdaq stockholmKarolinska developmentNasdaq stockholmUmecrine cognitionGeneral counselKarolinska development ab publ stock exchangePress releaseF kdev se0002190926

Karolinska Development s portfolio company AnaCardio recruits first patient to a clinical trial of its drug candidate AC01

STOCKHOLM, SWEDEN April 13, 2023. Karolinska Development AB today announces that its portfolio company AnaCardio has included the first patient in the company’s clinical phase 1b/2a study of. | April 13, 2023

United kingdomGreat britainViktor drvotaKarolinska institutetJohan dighedKarolinska developmentKarolinska development ab nasdaq stockholmKarolinska university hospitalNasdaq stockholmWorldwide clinicalGeneral counselKarolinska development ab publ stock exchangePress releaseTudy kdev se0002190926

Karolinska Development s portfolio company AnaCardio

STOCKHOLM, SWEDEN April 13, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has included the.

United kingdomGreat britainKarolinska institutetViktor drvotaJohan dighedKarolinska university hospitalKarolinska developmentKarolinska development ab nasdaq stockholmNasdaq stockholmWorldwide clinicalGeneral counselStockholm stock exchange kdevArolinska development ab publ

Karolinska Development s portfolio company Umecrine Cognition secures additional funding for further development of golexanolone

STOCKHOLM, SWEDEN – March 28, 2023. Karolinska Development AB today announces that the portfolio company Umecrine Cognition has secured additional funding for the continued development of the. | March 28, 2023

Viktor drvotaKarolinska institutetJohan dighedKarolinska development ab nasdaq stockholmKarolinska developmentNasdaq stockholmUmecrine cognitionGeneral counselKarolinska development ab publ stock exchangePress releaseF kdev se0002190926

Karolinska Development AB (publ): Karolinska Development Annual Report 2022 published

STOCKHOLM, SWEDEN - March 24, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces publication of its Annual Report 2022. The report is now available to download at www.karolinskadevelopment.com

Karolinska institutetViktor drvotaKarolinska development ab nasdaq stockholmKarolinska developmentNasdaq stockholmAnnual reportDiese gold aktieSichern sie

vimarsana © 2020. All Rights Reserved.